Drybench Patent.
DOXYCYCLINE HYCLATE, NDA 050795
The patents and exclusivities FDA's Orange Book lists for NDA 050795 as captured on 14 October 2026, each date named by its rule and its rows, and the rows of FDA's Paragraph IV list that give this NDA's number, as captured on 17 October 2026. Listed protection is a range of dates, never one date.
FDA capture · review pending. Each row is shown as captured from FDA's Orange Book files and Paragraph IV list. Dates are FDA's own; spreadsheet day numbers are shown as dates, and a cell that cannot be read as one date is shown as written and left out of the range. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. A Paragraph IV row is placed here only by the number in its RLD/NDA cell; nothing is joined by name. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.
- Orange Book captured
- 14 October 2026
- Paragraph IV list captured
- 17 October 2026
- Last checked
- 30 October 2026
- Data-branch commit
- dadcab56563716abea6c5e31a5e1970080c778ef
Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.
Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.
Listed protection
Listed dates run from 3 Feb 2028 to 23 Dec 2034, each by its own rule; no one date stands for this product.
- Earliest listed date
- 3 Feb 2028US 8,715,724, product patentRule R1 · Products 001, 002, 003, 004, 005, 006, 007, 008 · patent.txt lines 2,145–2,151, 2,155
- Latest listed date
- 23 Dec 2034US 9,446,057, product and use patentRule R1 · Products 007, 008 · patent.txt lines 2,153, 2,157
- Latest substance patent
- None listed
- Latest listed patent
- 23 Dec 2034US 9,446,057, product and use patentRule R1 · Products 007, 008 · patent.txt lines 2,153, 2,157
- Latest exclusivity
- None listed
4 use-code patents, blocking the coded use only
Products
Each product number FDA lists under NDA 050795, as listed. The sections below name products by these numbers.
Product 001 · DORYX
- Dosage form; route
- TABLET, DELAYED RELEASE;ORAL
- Strength
- EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- Approval date as listed
- 6 May 2005
- Type as listed
- DISCN
- Applicant as listed
- MAYNE PHARMA INTERNATIONAL PTY LTD
Product 002 · DORYX
- Dosage form; route
- TABLET, DELAYED RELEASE;ORAL
- Strength
- EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- Approval date as listed
- 6 May 2005
- Type as listed
- DISCN
- Applicant as listed
- MAYNE PHARMA INTERNATIONAL PTY LTD
Product 003 · DORYX
- Dosage form; route
- TABLET, DELAYED RELEASE;ORAL
- Strength
- EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- Approval date as listed
- 20 Jun 2008
- Type as listed
- DISCN
- Applicant as listed
- MAYNE PHARMA INTERNATIONAL PTY LTD
Product 004 · DORYX
- Dosage form; route
- TABLET, DELAYED RELEASE;ORAL
- Strength
- EQ 80MG BASE
- Approval date as listed
- 11 Apr 2013
- Type as listed
- DISCN
- Applicant as listed
- MAYNE PHARMA INTERNATIONAL PTY LTD
Product 005 · DORYX
- Dosage form; route
- TABLET, DELAYED RELEASE;ORAL
- Strength
- EQ 200MG BASE
- Approval date as listed
- 11 Apr 2013
- Type as listed
- DISCN
- Applicant as listed
- MAYNE PHARMA INTERNATIONAL PTY LTD
Product 006 · DORYX
- Dosage form; route
- TABLET, DELAYED RELEASE;ORAL
- Strength
- EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- Approval date as listed
- 19 Dec 2014
- Type as listed
- DISCN
- Applicant as listed
- MAYNE PHARMA INTERNATIONAL PTY LTD
Product 007 · DORYX MPC
- Dosage form; route
- TABLET, DELAYED RELEASE;ORAL
- Strength
- EQ 60MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- Approval date as listed
- 20 May 2016
- Type as listed
- RX
- Applicant as listed
- MAYNE PHARMA INTERNATIONAL PTY LTD
Product 008 · DORYX MPC
- Dosage form; route
- TABLET, DELAYED RELEASE;ORAL
- Strength
- EQ 120MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- Approval date as listed
- 20 May 2016
- Type as listed
- DISCN
- Applicant as listed
- MAYNE PHARMA INTERNATIONAL PTY LTD
Listed patents
Every patent the FDA lists for this product, as the application holder submitted it, with its flags. The FDA does not verify listings.
4 entries from 14 rows as listed; rows merge only where every cell shown is the same, each with its product numbers.
US 8,715,724, product patent
patent.txt lines 2,145–2,151, 2,155- Expiry as listed
- 3 Feb 2028
- Rule
- R1
- Flags
- product
- Product numbers
- 001, 002, 003, 004, 005, 006, 007, 008
US 9,295,652, product and use patent
patent.txt lines 2,152, 2,156- Expiry as listed
- 23 Oct 2034
- Rule
- R1
- Flags
- product · use code U-918
- Product numbers
- 007, 008
US 9,511,031, product patent
patent.txt lines 2,154, 2,158- Expiry as listed
- 23 Oct 2034
- Rule
- R1
- Flags
- product
- Product numbers
- 007, 008
US 9,446,057, product and use patent
patent.txt lines 2,153, 2,157- Expiry as listed
- 23 Dec 2034
- Rule
- R1
- Flags
- product · use code U-918
- Product numbers
- 007, 008
Listed exclusivities
Each exclusivity FDA lists for NDA 050795, with its code, FDA's definition of the code where the store's code list gives one, and its date as listed.
The Orange Book capture of 14 October 2026 lists no exclusivity for NDA 050795.
Paragraph IV list rows giving NDA 050795
The rows of FDA's Paragraph IV certifications list as captured on 17 October 2026 whose RLD/NDA cell gives NDA 050795, each cell as listed.
FDA's Paragraph IV list names no patent number, so it does not say which of the patents on this page an applicant certified against.
The list gives the last qualifying patent's expiry without pediatric exclusivity; in the app's Patents view, the Orange Book lists any *PED period as a separate row with its own date. The two dates describe different things. A blank cell is one FDA left blank in its list. Dates are FDA's own; the last qualifying patent expiry is not recomputed from the Orange Book.
Rows whose RLD/NDA cell we could not read as exactly one NDA number are kept apart on the list page; some may concern this product.
Rows on FDA's Paragraph IV list whose RLD/NDA cell gives NDA 050795
Doxycycline Hyclate · Delayed-release Tablets · 150 mg
RLD/NDA as listed: Doryx 50795- First PIV submission
- 19 Dec 2008
- ANDAs
- 1
- 180-day status
- Extinguished
- Decision posted
- 7 Apr 2020
- First applicant approval
- blank
- First marketing
- blank
- Last qualifying patent expiry (as listed by FDA)
- 15 Dec 2022
Doxycycline Hyclate · Delayed-release Tablets · 200 mg
RLD/NDA as listed: Doryx 50795- First PIV submission
- 19 May 2014
- ANDAs
- 1
- 180-day status
- Eligible
- Decision posted
- 7 Apr 2020
- First applicant approval
- 19 May 2016
- First marketing
- 19 May 2016
- Last qualifying patent expiry (as listed by FDA)
- 15 Dec 2022
Doxycycline Hyclate · Delayed-release Tablets · 75 mg and 100 mg
RLD/NDA as listed: Doryx 50795- First PIV submission
- PIV received prior to 2/5/2009
- ANDAs
- 1
- 180-day status
- Eligible
- Decision posted
- 7 Apr 2020
- First applicant approval
- 28 Dec 2010
- First marketing
- 30 Dec 2010
- Last qualifying patent expiry (as listed by FDA)
- 15 Dec 2022
Doxycycline Hyclate · Delayed-release Tablets · 50 mg
RLD/NDA as listed: Doryx 50795- First PIV submission
- 5 Nov 2015
- ANDAs
- 1
- 180-day status
- Eligible
- Decision posted
- 7 Apr 2020
- First applicant approval
- 23 May 2016
- First marketing
- 23 May 2016
- Last qualifying patent expiry (as listed by FDA)
- 3 Feb 2028
Doxycycline Hyclate · Delayed-release Tablets · 60 mg and 120 mg
RLD/NDA as listed: Doryx MPC 50795- First PIV submission
- 28 Sep 2017
- ANDAs
- 1
- 180-day status
- Extinguished
- Decision posted
- 7 Aug 2023
- First applicant approval
- blank
- First marketing
- blank
- Last qualifying patent expiry (as listed by FDA)
- 23 Dec 2034
Doxycycline Hyclate · Delayed-release Tablets · 80 mg
RLD/NDA as listed: Doryx 50795- First PIV submission
- 1 Jul 2015
- ANDAs
- 1
- 180-day status
- Extinguished Eligible
- Decision posted
- 4/18/2023 4/7/2020
- First applicant approval
- 29 Apr 2016
- First marketing
- blank
- Last qualifying patent expiry (as listed by FDA)
- 15 Dec 2022
Notes from the trace
- R6 tentative approvals: not in the Orange Book data files as captured; the Drugs@FDA join is a later ruling.
Patents vs FDA exclusivityHow to read the Orange Book data filesParagraph IV certificationWhat changed, by week